Home » Stocks » ONCR

Oncorus, Inc. (ONCR)

Stock Price: $14.47 USD -0.23 (-1.56%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $14.63 +0.16 (1.11%) May 13, 4:11 PM
Market Cap 369.91M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 25.63M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $14.47
Previous Close $14.70
Change ($) -0.23
Change (%) -1.56%
Day's Open 14.95
Day's Range 14.24 - 15.14
Day's Volume 77,795
52-Week Range 11.50 - 37.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H'21 -- -- Company plans to nomi...

1 week ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, NEXI ...
2 months ago - Benzinga

These are 7 of the best swing trade stocks on the market right now, but you need to have a strategy and rules in order to be safe. The post 7 of the Best Swing Trade Stocks Available Right Now appeared ...

Other stocks mentioned: GOOGL, GS, LMB, PD, UL, XLRE
2 months ago - InvestorPlace

Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on t...

3 months ago - Benzinga

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...

3 months ago - GlobeNewsWire

Oncorus Inc.'s share price has risen by over 120% in about three months of listing. ONCR's novel technology is still a reason to consider the stock as an investment in emerging biopharmaceutical, but th...

3 months ago - Seeking Alpha

-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its  five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor...

3 months ago - GlobeNewsWire

-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product  pipeline of intratumorally and intravenously administered viral immunotherapies –

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today ...

5 months ago - GlobeNewsWire

-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outc...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer...

7 months ago - GlobeNewsWire

Oncorus Finalizes $87 Million U.S. IPO Effort

7 months ago - Seeking Alpha

Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each.

7 months ago - Market Watch

About ONCR

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 2, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ONCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Oncorus stock is "Strong Buy." The 12-month stock price forecast is 37.75, which is an increase of 160.88% from the latest price.

Price Target
$37.75
(160.88% upside)
Analyst Consensus: Strong Buy